共被期刊论文引用了3次
您的检索式：您选中1篇文献正在查看引证文献汇总
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | TGF-β1 gene-modified,immature dendritic cells delay the development of inflammatory bowel disease by inducing CD4^(+)Foxp3^(+)regulatory T cells显示文摘Inflammatory bowel disease(IBD)is caused by an uncontrolled immune response in the intestinal lumen,leading to inflammation in genetically predisposed individuals.Immunotherapy may be a promising approach to the treatment of IBD.Here,we show that transforming growth factor-β1(TGF-β1)gene-modified immature dendritic cells(imDCs)could enhance the inhibitory function of imDCs and delay the progress of IBD induced by dextran sodium sulfate in mice.The results of fluorescence-activated cell sorter(FACS)demonstrated that this protective effect is mediated partially by inducing CD4^(+)Foxp3^(+)regulatory T cells(Tregs)in mesentery lymph nodes to control inflammation.In vitro experiments also supported this hypothesis.In conclusion,we provide evidence that TGF-b1-modified bone marrow-derived imDCs may have a therapeutic effect to IBD. | Zhijian Cai Wei Zhang Min Li Yinpu Yue Fei Yang Lei Yu Xuetao Cao Jianli Wang | 2010 | Cellular & Molecular Immunology2010，7，1： | 18 |
| 2 | 炎症性肠病的致病机理和治疗研究进展显示文摘炎症性肠病(IBD),主要指克隆病(CD)和溃疡性结肠炎(UC),同时也包括一些其它非传染性的肠道炎症,是一类以免疫应答失调导致持续性肠道炎症为特征的疾病。IBD的病因和确切的发病机制目前还并不明确,一般认为是在遗传易感性的个体身上,由于环境因素,遗传因素,以及免疫因素等各方面的综合作用,肠道粘膜免疫系统对肠道微生物菌群发生了过度的免疫反应而最终导致了肠道炎症。IBD传统的治疗方法并没有很好的效果并常常伴随着强烈的副作用。近些年来随着对免疫因素在IBD发病中所起作用的研究日益深入,不断出现着一些针对IBD发病机制的新的疗法。 | 张伟 王建莉 | 2009 | 国际免疫学杂志2009，32，2： | 2 |
| 3 | Quality of care for patients with inflammatory bowel disease in East China显示文摘AIM: To investigate the quality of care for a hospital based-cohort of patients with inflammatory bowel disease (IBD) from East China according to the current practice guidelines. METHODS: A retrospective review was conducted,involving 177 patients with IBD admitted to Sir Run Run Shaw Hospital,College of Medicine,Zhejiang University between June 2000 and June 2006. Data regarding demographic and clinical characteristics as well as medical therapy including use of oral aminosalisylates,topical therapy,corticosteroid agents,immunomodulatory agents (such as azathioprine) at admission and outpatient clinic visit were analyzed. RESULTS: A total of 177 eligible patients were evaluated in this study,including 71 patients with Crohn's disease (CD) and 106 with ulcerative colitis (UC). All were the Han nationality Chinese with active disease at baseline. All the 106 patients with ulcerative colitis received optimal doses of aminosalisylate while 27 of 68 (39.7%) patients with ileal or colonic CD received the suboptimal doses of aminosalisylate. The incidence of suboptimal dose of aminosalisylate was significantly higher in CD patients with small intestine involvement only (52.8% vs 25.0%,P = 0.019). Thirty-one (54.4%) patients with active distal or left-sided ulcerative colitis received topical therapy,and 27.8% of patients suffering from severe in? ammatory bowel disease did not receive oral or intravenous steroid therapy. Among the 51 patients for whom thiopurine was indicated,only 10 (19.6%)received immunomodulatory agents,and more than half of the 8 patients received a suboptimal dose of azathiopurine with no attempt to increase its dosage. CONCLUSION: The quality of care for IBD patients can be further improved. A suboptimal dose of aminosalicylate is used in treatment of patients with CD,especially in those with small intestine involved only. Topical mesalazine is inadequately used in patients with distal or left-sided colitis. Oral or intravenous steroid therapy is not used in some patients with severe IBD. Use of immunomodulatory medication is limited. Larger prospective studies are needed to investigate the quality of care for patients with IBD to establish our own evidence-based guidelines. | Qin Zhu Qian Cao Jian-Min Si | 2008 | World Journal of Gastroenterology2008，14，4： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员